» Articles » PMID: 15720813

Gene Expression Profile of Glioblastoma Multiforme Invasive Phenotype Points to New Therapeutic Targets

Overview
Journal Neoplasia
Publisher Elsevier
Specialty Oncology
Date 2005 Feb 22
PMID 15720813
Citations 159
Authors
Affiliations
Soon will be listed here.
Abstract

The invasive phenotype of glioblastoma multiforme (GBM) is a hallmark of malignant process, yet molecular mechanisms that dictate this locally invasive behavior remain poorly understood. Gene expression profiles of human glioma cells were assessed from laser capture-microdissected GBM cells collected from paired patient tumor cores and white matter-invading cell populations. Changes in gene expression in invading GBM cells were validated by quantitative reverse transcription polymerase chain reaction (QRT-PCR) and immunohistochemistry in an independent sample set. QRT-PCR confirmed the differential expression in 19 of 21 genes tested. Immunohistochemical analyses of autotaxin (ATX), ephrin B3, B-cell lymphoma-w (BCLW), and protein tyrosine kinase 2 beta showed them to be expressed in invasive glioma cells. The known GBM markers, insulin-like growth factor binding protein 2 and vimentin, were robustly expressed in the tumor core. A glioma invasion tissue microarray confirmed the expression of ATX and BCLW in invasive cells of tumors of various grades. GBM phenotypic and genotypic heterogeneity is well documented. In this study, we show an additional layer of complexity: transcriptional differences between cells of tumor core and invasive cells located in the brain parenchyma. Gene products supporting invasion may be novel targets for manipulation of brain tumor behavior with consequences on treatment outcome.

Citing Articles

Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.

Villegas-Vazquez E, Marin-Carrasco F, Reyes-Hernandez O, Baez-Gonzalez A, Bustamante-Montes L, Padilla-Benavides T Front Oncol. 2025; 14:1514120.

PMID: 39876896 PMC: 11772297. DOI: 10.3389/fonc.2024.1514120.


Differential Effects of Extracellular Vesicles from Two Different Glioblastomas on Normal Human Brain Cells.

Wang M, Graner A, Knowles B, McRae C, Fringuello A, Paucek P Neurol Int. 2024; 16(6):1355-1384.

PMID: 39585062 PMC: 11587087. DOI: 10.3390/neurolint16060103.


DDX3X dynamics, glioblastoma's genetic landscape, therapeutic advances, and autophagic interplay.

Sharma A, Raut S, Shukla A, Gupta S, Singh A, Mishra A Med Oncol. 2024; 41(11):258.

PMID: 39368002 DOI: 10.1007/s12032-024-02525-z.


Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.

Laface C, Ricci A, Vallarelli S, Ostuni C, Rizzo A, Ambrogio F Int J Mol Sci. 2024; 25(14).

PMID: 39062979 PMC: 11277072. DOI: 10.3390/ijms25147737.


A single-cell atlas deconstructs heterogeneity across multiple models in murine traumatic brain injury and identifies novel cell-specific targets.

Jha R, Rajasundaram D, Sneiderman C, Schlegel B, OBrien C, Xiong Z Neuron. 2024; 112(18):3069-3088.e4.

PMID: 39019041 PMC: 11578855. DOI: 10.1016/j.neuron.2024.06.021.


References
1.
Miyazaki T, Reed J . A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins. Nat Immunol. 2001; 2(6):493-500. DOI: 10.1038/88684. View

2.
Maher E, Furnari F, Bachoo R, Rowitch D, Louis D, Cavenee W . Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001; 15(11):1311-33. DOI: 10.1101/gad.891601. View

3.
Mariani L, Beaudry C, McDonough W, Hoelzinger D, Kaczmarek E, Ponce F . Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res. 2001; 7(8):2480-9. View

4.
Louis D, Holland E, Cairncross J . Glioma classification: a molecular reappraisal. Am J Pathol. 2001; 159(3):779-86. PMC: 1850454. DOI: 10.1016/S0002-9440(10)61750-6. View

5.
Rickman D, Bobek M, Misek D, Kuick R, Blaivas M, Kurnit D . Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001; 61(18):6885-91. View